XLRN insider filings
ACCELERON PHARMA INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-22. Screen XLRN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for XLRN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ACCELERON PHARMA INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-11-22 | 4 | Zakrzewski Joseph S — Director | Code (U): 34,499 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · +2 more | EDGAR |
| 2021-11-22 | 4 | Malik Kemal — Director | Code (U): 1,622 · Disposition to issuer (D): 17,956 (derivative) · Disposition to issuer (D): 3,222 (derivative) | EDGAR |
| 2021-11-22 | 4 | Hite Christopher — Director | Code (U): 930 · Disposition to issuer (D): 10,267 (derivative) · Disposition to issuer (D): 1,848 (derivative) | EDGAR |
| 2021-11-22 | 4 | Smith Karen L. — Director | Code (U): 1,622 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 1,875 (derivative) · Disposition to issuer (D): 3,750 (derivative) · Disposition to issuer (D): 4,085 (derivative) · Disposition to issuer (D): 3,222 (derivative) | EDGAR |
| 2021-11-22 | 4 | MCCOURT Thomas A — Director | Code (U): 6,044 · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 8,185 (derivative) · Disposition to issuer (D): 3,222 (derivative) | EDGAR |
| 2021-11-22 | 4 | Kearney Terrence C — Director | Code (U): 6,749 · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 4,665 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 8,185 (derivative) · Disposition to issuer (D): 3,222 (derivative) | EDGAR |
| 2021-11-22 | 4 | Hamill Laura — Director | Code (U): 474 · Disposition to issuer (D): 9,339 (derivative) · Disposition to issuer (D): 941 (derivative) | EDGAR |
| 2021-11-22 | 4 | Nader Francois — Director | Code (U): 6,749 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 576 (derivative) · +4 more | EDGAR |
| 2021-11-22 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Code (U): 23,423 · Disposition to issuer (D): 6,700 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 24,334 (derivative) · Disposition to issuer (D): 18,806 (derivative) | EDGAR |
| 2021-11-22 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Code (U): 18,509 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,500 (derivative) · Disposition to issuer (D): 24,334 (derivative) · Disposition to issuer (D): 20,896 (derivative) | EDGAR |
| 2021-11-22 | 4 | Backstrom Jay T. — EVP, Research and Development | Code (U): 21,233 · Disposition to issuer (D): 96,963 (derivative) · Disposition to issuer (D): 20,896 (derivative) | EDGAR |
| 2021-11-22 | 4 | Dable Habib J — CEO and President, Director | Code (U): 98,450 · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 108,800 (derivative) · Disposition to issuer (D): 106,400 (derivative) · Disposition to issuer (D): 84,720 (derivative) · Disposition to issuer (D): 64,361 (derivative) | EDGAR |
| 2021-11-22 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Code (U): 10,681 · Disposition to issuer (D): 2,663 (derivative) · Disposition to issuer (D): 11,262 (derivative) · Disposition to issuer (D): 20,500 (derivative) · Disposition to issuer (D): 24,334 (derivative) · Disposition to issuer (D): 18,806 (derivative) | EDGAR |
| 2021-11-12 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Option exercise (M): 4,500 @ $29.37 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2021-09-27 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Option exercise (M): 5,000 @ $40.61 · Sale (S): 5,000 @ $175 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-09-24 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Option exercise (M): 2,500 @ $30.17 · Option exercise (M): 9,800 @ $40.61 · Option exercise (M): 7,330 @ $41.64 · Sale (S): 18,647 @ $160.26 · Sale (S): 983 @ $161.26 · Option exercise (M): 5,200 @ $40.61 · +7 more | EDGAR |
| 2021-09-22 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Option exercise (M): 5,200 @ $30.17 · Option exercise (M): 1,450 @ $41.20 · Sale (S): 6,650 @ $150.05 · Option exercise (M): 5,200 (derivative) @ $0 · Option exercise (M): 1,450 (derivative) @ $0 | EDGAR |
| 2021-09-22 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Option exercise (M): 5,000 @ $40.61 · Sale (S): 5,000 @ $150.03 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-09-09 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Tax withholding (F): 587 @ $129.36 · Sale (S): 6 @ $130 · Sale (S): 1,407 @ $130 | EDGAR |
| 2021-07-02 | 4 | Dable Habib J — CEO and President, Director | Option exercise (M): 57,814 @ $35.04 · Sale (S): 11,845 @ $125.15 · Sale (S): 9,194 @ $125.81 · Sale (S): 23,160 @ $126.85 · Sale (S): 4,560 @ $127.89 · Sale (S): 9,055 @ $128.82 · +6 more | EDGAR |
| 2021-06-08 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Tax withholding (F): 108 @ $126.69 | EDGAR |
| 2021-06-08 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Tax withholding (F): 887 @ $130.87 | EDGAR |
| 2021-04-21 | 4 | MCCOURT Thomas A — Director | Option exercise (M): 7,500 @ $40.61 · Sale (S): 2,127 @ $118.39 · Sale (S): 4,030 @ $119.36 · Sale (S): 1,143 @ $120.16 · Sale (S): 200 @ $121.23 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2021-04-05 | 4 | Zakrzewski Joseph S — Director | Option exercise (M): 10,000 @ $24.11 · Sale (S): 6,748 @ $140.31 · Sale (S): 2,152 @ $141.28 · Sale (S): 1,100 @ $142.27 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-04-05 | 4 | Smith Karen L. — Director | Option exercise (M): 5,000 @ $35.34 · Option exercise (M): 1,875 @ $41.64 · Option exercise (M): 2,050 @ $52.99 · Sale (S): 11,223 @ $140.13 · Sale (S): 641 @ $141.15 · Option exercise (M): 5,000 (derivative) @ $0 · +2 more | EDGAR |
| 2021-04-02 | 4 | Zakrzewski Joseph S — Director | Option exercise (M): 10,000 @ $24.11 · Sale (S): 104 @ $132.61 · Sale (S): 6,596 @ $134.27 · Sale (S): 1,700 @ $135.22 · Sale (S): 1,600 @ $135.67 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-04-02 | 4 | Smith Karen L. — Director | Option exercise (M): 5,000 @ $35.34 · Option exercise (M): 1,875 @ $41.64 · Option exercise (M): 2,050 @ $52.99 · Sale (S): 1,201 @ $134.54 · Sale (S): 2,987 @ $136.22 · Sale (S): 3,796 @ $136.92 · +4 more | EDGAR |
| 2021-03-04 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Option exercise (M): 5,000 @ $40.61 · Sale (S): 2,699 @ $135.48 · Sale (S): 1,501 @ $136.24 · Sale (S): 600 @ $137.12 · Sale (S): 200 @ $138.15 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Grant/award (A): 4,868 @ $0 · Grant/award (A): 18,806 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Grant/award (A): 5,409 @ $0 · Grant/award (A): 20,896 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Backstrom Jay T. — EVP, Research and Development | Grant/award (A): 5,409 @ $0 · Grant/award (A): 20,896 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Dable Habib J — CEO and President, Director | Grant/award (A): 16,662 @ $0 · Grant/award (A): 64,361 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Zakrzewski Joseph S — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Smith Karen L. — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | MCCOURT Thomas A — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Malik Kemal — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Kearney Terrence C — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Hite Christopher — Director | Grant/award (A): 930 @ $0 · Grant/award (A): 1,848 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Hamill Laura — Director | Grant/award (A): 474 @ $0 · Grant/award (A): 941 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | Nader Francois — Director | Grant/award (A): 1,622 @ $0 · Grant/award (A): 3,222 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4/A | KANGO SUJAY — EVP, Chief Commercial Officer | Option exercise (M): 10,000 @ $40.61 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Grant/award (A): 4,868 @ $0 · Grant/award (A): 18,806 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | Veness Adam M — SVP, General Counsel and Sec. | Tax withholding (F): 942 @ $124.31 · Sale (S): 1,900 @ $122.46 · Sale (S): 56 @ $122.93 · Sale (S): 100 @ $124.30 | EDGAR |
| 2021-01-06 | 4 | KANGO SUJAY — EVP, Chief Commercial Officer | Tax withholding (F): 1,357 @ $124.31 · Sale (S): 1,947 @ $123.90 · Sale (S): 3,429 @ $125.17 · Sale (S): 4,624 @ $126.15 | EDGAR |
| 2021-01-06 | 4 | Backstrom Jay T. — EVP, Research and Development | Tax withholding (F): 1,735 @ $124.31 | EDGAR |
| 2021-01-06 | 4 | Dable Habib J — CEO and President, Director | Tax withholding (F): 3,278 @ $124.31 · Sale (S): 2,500 @ $120.52 · Sale (S): 900 @ $121.55 · Sale (S): 764 @ $122.46 · Sale (S): 94 @ $122.55 | EDGAR |
| 2021-01-06 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Tax withholding (F): 624 @ $124.31 · Sale (S): 800 @ $123.54 · Sale (S): 713 @ $124.28 · Sale (S): 200 @ $125.49 · Sale (S): 600 @ $123.49 · Sale (S): 667 @ $124.47 · +5 more | EDGAR |
| 2020-12-15 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Option exercise (M): 7,252 @ $41.20 · Option exercise (M): 7,700 @ $27.97 · Option exercise (M): 24,986 @ $30.17 · Option exercise (M): 2,590 @ $40.61 · Sale (S): 42,528 @ $130.14 · Option exercise (M): 7,252 (derivative) @ $0 · +3 more | EDGAR |
| 2020-12-11 | 4 | MCLAUGHLIN KEVIN F — SVP, CFO and Treasurer | Option exercise (M): 548 @ $41.20 · Option exercise (M): 400 @ $27.97 · Option exercise (M): 1,051 @ $30.17 · Option exercise (M): 1,873 @ $40.61 · Sale (S): 3,872 @ $125.03 · Option exercise (M): 100 @ $41.20 · +15 more | EDGAR |
| 2020-10-13 | 4 | Kearney Terrence C — Director | Option exercise (M): 20,000 @ $28.37 · Option exercise (M): 10,000 @ $27.97 · Option exercise (M): 7,500 @ $30.17 · Sale (S): 2,200 @ $117.82 · Sale (S): 18,177 @ $119.11 · Sale (S): 16,210 @ $119.78 · +4 more | EDGAR |
Recent 8-K events — ACCELERON PHARMA INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-11-22 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-27 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2021-09-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-07-28 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2021-06-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-06-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2021-06-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-05-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=XLRN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs